Since decisions by healthcare insurers can be draconian, fostering a collegial relationship with a healthcare insurer’s negotiator can help forge agreements between providers, payers
ACR Board of Directors Advocates for Rheumatology on Capitol Hill
Members meet with Congress this month to discuss access to rheumatology, access to treatments, and funding for research
Sequester Affects Rheumatologists on Two Fronts—Medicare Reimbursement and Research Funding
Rheumatologists are already feeling two effects from Congress’ inability to solve sequestration: a 2% reduction in Medicare reimbursements and slashed funding for research financed by the National Institutes of Health.
President’s Perspective: ACR Calls on Members to Advance Rheumatology
Members’ support and participation is needed to strengthen the ACR’s lobbying efforts with Congress
How Rheumatologists Can Win Support and Influence Congress
Ways to use the ACR’s advocacy toolkit to contact Congressional representatives and articulate your message to lawmakers
Department of Health and Human Services’ Final Rule Expands HIPAA Obligations, Violation Penalties
Physicians’ business associates can now face civil and criminal penalties for violating HIPAA laws guarding the confidentiality of protected health information
Why Universal Access to Healthcare Isn’t a Constitutional Right, It’s Just Plain Fair
One rheumatologist forms his opinion on the topic while fly fishing on rivers in Missouri
ACR Advances Legislation to Increase Patients’ Access to Biologic Drugs to Treat Rheumatoid Arthritis and Other Conditions
The Patients’ Access to Treatments Act of 2013 would prevent insurance companies from tacking on an additional cost-sharing fee for the specialty medications
Five Quick Ways To Make a Difference in Rheumatology Through Advocacy
The ACR’s online advocacy page has position statements and work plans on issues affecting rheumatology, and offers ways to get involved
ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
The Biologics Price Competition and Innovation Act of 2009 would spur the development of products intended to be biosimilar to approved therapies
- « Previous Page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- …
- 86
- Next Page »